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I read with interest the article of Dubois et al. pub-
lished in your journal in January 2003: ‘‘Bronchodilating
e¡ects of cumulative doses of formoterol from a novel
multi-dose inhaler (Airmaxs) (1).The authors state that
formoterol delivered fromAirmaxs provides a dose-de-
pendent bronchodilating e¡ect which is similar to that
obtainedby Aerolisers at double the dose: so according
to this study, there exists a1:2 doserelationbetweenAir-
maxs and Aerolisers.
However, formoterol does not provide a dose-depen-
dent e¡ect up to 8^10h after inhalation of medication
(2,3), while the observation period in this study is short-
er: 4.30h. No dose-dependent bronchodilating e¡ect of
formoterol on FEV1 can be seen in a dose range of 12^
120mg either (4).Therefore, the conclusion made by the
authors cannot be correct because the results of this
study are most likely driven by the study design and not
by the di¡erent types of inhalers used. It would be inter-
esting to know, whether the same conclusion could be
madewhen an additional treatment armwith cumulative
doses of formoterolAirmaxs12, 24,48 and 96mg and/or
formoterol Aerolisers 6,12, 24 and 48mg were included.
Moreover, as Fishwicket al. demonstrated in their study,
conclusions with respect to the relative dose-potencies
of investigated drugs and/or devices can only be made,
when signi¢cant shifts between the cumulative dose re-
sponse curves can be shown (5).This is however not de-
monstrated in the study by EFLDubois et al.
H.J.VAN DERWOUDE
Schaepmanlaan 51,9722 NRGroningen,
The Netherlands.
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Firstly Iwould like to thankDr van der Woude for her
well-documented and challenging remarks on our study.
Her statement however that there exists no dose de-
pendency between the e¡ect (FEV1) and the adminis-
tered dose, cannot be excluded by the references she
quoted. Firstly, there are other references which have
not been quoted, which do sustain the perception that
there is a dose dependency asmentioned. (1^3) Secondly,
neither of these studies, including ours, is designed tode-
termine the pharmacological potency of this drug. For
this pharmacodynamic and pharmacokinetic studies are
necessary, which have been performed by our group (4),
illustrating that not only a concentration e¡ect relation-
ship may exist. Moreover, this relationship seems to be
dependent of inhaled fraction, when considering the on-
set of action and the oropharyngeal deposited fraction,
as far as the length of the bronchodilating e¡ect is con-
cerned. Evenmore, these studies leave out the in£uence
of formoterolbeing a racemate, existing of RR (e¡ective)
and SS enantiomers ( far less e¡ective) (5,6).
Our study was designed to showa clinical doseequiva-
lence of a newmultidose inhaler (Airmaxs) compared to
the originally registered device (Aerolizers), as has been
done beforewith othermdpi devices (7).The cumulative
dose design was adapted from earlier studies (2,3) and
did show a step by step dose dependency in both arms
in a 1:2 ratio.We did not continue measurements after
4:30h, because we did not expect the maximal achiev-
able FEV1to be di¡erent since in both arms themaximal
dose e¡ect was achieved. We agree with Dr van der
Woude that statistical and clinical signi¢cant di¡erence
in dose response can only be demonstratedwith a signif-
icant shift in the dose reponse curve. However, we did
not show any signi¢cant shifts between the cumulative
dose response curves. It would have been illustrative to
compare the novel device with the Aerolizers 6mg;
however, this formulation does not exist.Within the lim-
its of the studydesign, notbeing apharmacodynamic and
pharmacokinetic study, we maintain our conclusions of
the study.
E.F.L DUBOIS
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